BCM
AVXL icon

BlueCrest Capital Management’s Anavex Life Sciences AVXL Stock Holding History

BlueCrest Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-69,985
Closed -$191K – 872
2018
Q3 		$191K Sell
69,985
-100,717
-59% -$284K 0.01% 1285
2018
Q2 		$447K Buy
+170,702
New +$477K 0.01% 897

Other funds holding AVXL

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlueCrest Capital Management's AVXL Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Anavex Life Sciences (AVXL) in Q4 2018, closing a stake of 69,985 shares — an estimated $191K sold.

BlueCrest Capital Management first reported a position in AVXL in Q2 2018 and held it in 2 quarters. The position peaked at $447K in Q2 2018. 49 funds tracked by Wall St. Rank hold AVXL as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Anavex Life Sciences position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 69,985 Anavex Life Sciences shares in Q4 2018, an estimated $191K.
  • BlueCrest Capital Management first reported a position in Anavex Life Sciences in Q2 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Anavex Life Sciences position peaked at $447K in Q2 2018.
  • 49 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.